GLP-1 clinical trials enrolling in the US
372 studies of GLP-1 medications, in plain English: who can join, what's involved, and where the sites are. Sourced from the official ClinicalTrials.gov registry.
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Studying: Ribupatide, Placebo · NCT07284901
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Studying: Ribupatide, Placebo · NCT07284875
The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness
Wellness · NCT07760896
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Studying: Survodutide, Placebo matching survodutide · NCT06632457
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Studying: Placebo, Survodutide · NCT07754461
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
Studying: Semaglutide 2.4 mg · NCT06934655
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes · NCT07387796
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Studying: aleniglipron, aleniglipron, aleniglipron · NCT07654374
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
Studying: AT673 low dose, AT673 high dose, Placebo · NCT07724340
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Studying: Ribupatide, Semaglutide, Placebo · NCT07284979
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Studying: Cagrilintide, Semaglutide, Placebo cagrilintide · NCT07253285
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Studying: Semaglutide Injectable Product (Wegovy and/or Ozempic) · NCT05819853
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Studying: Cagrisema, Semaglutide · NCT07564414
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Studying: Tirzepatide, Tirzepatide Placebo · NCT07191873
GLP-1R Agonist Treatment for Opioid Use Disorder
Studying: Semaglutide Pen Injector, Placebo · NCT06548490
GLP-1R Actions on Muscle and the Skeleton
Studying: Tirzepatide · NCT07154719
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Studying: Maridebart Cafraglutide · NCT07575399
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Studying: Orforglipron, Placebo · NCT06672549
Incretin Therapies in Obesity-related HFpEF
Studying: Tirzepatide · NCT07554638
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Studying: Orforglipron, Placebo · NCT06672939
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Studying: Orforglipron, Placebo · NCT07153471
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Studying: Tirzepatide, Retatrutide, Placebo · NCT07165028
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Studying: Orforglipron, Placebo · NCT07223593
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Studying: Survodutide, Placebo · NCT06632444
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Studying: Mirikizumab, Mirikizumab, Tirzepatide · NCT06937086
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Studying: Mirikizumab, Mirikizumab, Tirzepatide · NCT06937099
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Studying: LY3457263, Placebo · NCT06897475
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
Studying: Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B · NCT07723833
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Studying: Olatorepatide, Placebo · NCT07685808
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
Studying: Semaglutide, Placebo · NCT07770841
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
Studying: Tirzepatide, Placebo · NCT07218445
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
Studying: Antiandrogen Therapy, Semaglutide, Tirzepatide · NCT07202247
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
Studying: Dulaglutide, Placebo · NCT05478707
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
Studying: Liraglutide · NCT03883412
Tirzepatide in MetALD
Studying: Tirzepatide · NCT07046819
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)
Studying: Semaglutide, Placebo · NCT07218354
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Studying: Tirzepatide · NCT06651177
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
Studying: GLP-1RA · NCT07178145
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Studying: Semaglutide · NCT03884075
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Studying: GLP-1 agonists · NCT07111494
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
Studying: UBT251, UBT251 Placebo, Semaglutide · NCT07668388
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Studying: ALN-PNP, Tirzepatide, Placebo · NCT07527910
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Studying: Aleniglipron, Placebo · NCT07654361
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Studying: NNC0662-0419, Semaglutide, Placebo · NCT07415954
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Studying: Dulaglutide · NCT06739122
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Studying: Tirzepatide, Placebo · NCT06439277
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Studying: LY3305677, LY3841136, Tirzepatide · NCT06143956
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Studying: Orforglipron, Placebo · NCT07202884
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Studying: Semaglutide Pen Injector, Placebo · NCT06411210
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
Pulmonary Aspiration · NCT06654219
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
Studying: Apraglutide, Placebo · NCT07742735
Gestational Response, Outcomes, and Weight After GLP-1 Use
Pregnant Individuals, Obesity & Overweight, Gestational Weight Gain · NCT07743567
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
Studying: Semaglutide · NCT07428746
Fibrosis Lessens After Metabolic Surgery
Studying: Incretin-Based Therapy · NCT06374875
Tirzepatide Impact Assessment Study
Studying: GLP-1 Receptor Agonist Therapy · NCT07740291
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Studying: VX-201, semaglutide SC · NCT07673900
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Studying: Tirzepatide · NCT07573163
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Studying: Tirzepatide, Placebo, [11C]raclopride plus drug · NCT07559500
Lifestyle Change Implementation Research Network at PRC at UMass Chan
GLP - 1 · NCT07481305
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
Studying: Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg · NCT04055428
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
Studying: KAI-7535, Placebo · NCT07497880
Sit Less, Interact and Move More (SLIMM) 2 Study
Studying: Placebo, Semaglutide · NCT05173714
Pharmacogenetics of Response to GLP1R Agonists
Studying: Semaglutide Pen Injector [Ozempic] · NCT05071898
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Studying: Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet, Placebo liquid emulsion formulation · NCT07728383
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Studying: Glucagon-Like Peptide-1 Agonist (GLP-1) · NCT07702461
Effects of GLP-1 RAs on Human Lactation Outcomes
Studying: Injected GLP-1 Receptor Agonists and Dual Agonists · NCT07720414
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Studying: Tirzepatide · NCT07257484
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Studying: Liraglutide, Oral Semaglutide, Semaglutide · NCT07225816
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Studying: Ozempic® · NCT06967389
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Studying: Metformin, semaglutide, Anti-hypertensives · NCT06975111
Multi-Site Trial of Tirzepatide for Smoking Cessation
Studying: Tirzepatide · NCT07602699
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Studying: NLY01, Placebo · NCT07497399
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
Studying: Injectable semaglutide or injectable tirzepatide · NCT06575738
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Studying: Tirzepatide · NCT06934642
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
Studying: Elecoglipron, Semaglutide · NCT07662213
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Studying: NNC0662-0419, Semaglutide, NNC0662-0419 Placebo · NCT07639021
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
Studying: Semaglutide · NCT07091500
Study of Tirzepatide for Recovery and Alcohol Use Management
Studying: Tirzepatide · NCT06727331
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
Studying: oral semaglutide · NCT06003153
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Studying: Enobosarm, Semaglutide (Wegovy) weekly injection · NCT07446998
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Studying: Cagrilintide, Placebo (matched to Cagrilintide) · NCT07607587
Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease
Coronary Artery Stenosis · NCT05831085
The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication
Studying: GLP-1 RAs · NCT07652333
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Studying: Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone · NCT04114136
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Studying: IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo · NCT07651319
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Studying: icovamenib 100 mg, Placebo · NCT07502508
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Studying: Tirzepatide · NCT06864026
Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset) · NCT07641361
Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)
Obesity, Women (Between 30 to 60 Years Old) · NCT07480109
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
Studying: Glucagon-like peptide 1 receptor agonist · NCT07107334
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
Studying: Tirzepatide, Standard of care treatment · NCT06976853
Weight Loss in Adults Using Semaglutide (Real-world Study)
Studying: Semaglutide · NCT07627074
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Studying: Semaglutide Pen Injector, Placebo · NCT05424003
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
Studying: Tirzepatide · NCT07228741
Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists
Upper Endoscopy, GLP1-R-related Disease · NCT07006142
Glutide for Ending Methamphetamine
Studying: Semaglutide, Placebo · NCT07204249
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Studying: Tirzepatide · NCT06857942
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Studying: Semaglutide · NCT05822609
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Studying: MET233 and MET097, MET097 · NCT06924320
Graded Insulin Suppression Test P&F
Studying: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min · NCT06592261
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Studying: Hyperglycemic clamp · NCT05499702
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
Studying: Semaglutide (Rybelsus®), Placebo · NCT07221214
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Studying: Dulaglutide 0.75Mg/0.5Ml Inj Pen · NCT04731272
Study of Patients Being Treated With Anti-obesity Medication
Obesity and Overweight · NCT06790160
2024 Tirzepatide-Bariatric Surgery
Studying: tirzepatide · NCT06721507
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
Studying: Semaglutide 1.0 mg · NCT07223983
The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery
Studying: REMD-477 versus Placebo · NCT07212868
Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss
Studying: Mounjaro · NCT06734273
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
Heart Failure, Diabetes · NCT06593314
Slowly Digestible Carbohydrates for GLP-1 Secretion
Blood Glucose, GLP-1, Satiety · NCT07572513
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
Studying: Liraglutide, Liraglutide + Exercise training · NCT04575844
Tirzepatide in Obesity-Driven Endometrial Cancer
Studying: Tirzepatide · NCT07065552
Dietary Peanuts and Nutrition-Related Outcomes
Dietary Change, Obesity & Overweight, Food Acceptance · NCT07244458
Feasibility of Semaglutide in Advanced Lung Disease
Studying: Semaglutide Pen Injector · NCT05746039
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Studying: Tirzepatide, Pioglitazone · NCT06657209
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Studying: Exenatide · NCT05482789
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
PreDiabetes · NCT06424106
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Studying: Tradipitant, Placebo · NCT07446439
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
Studying: GLP-1 receptor agonist · NCT06903923
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Studying: Tirzepatide · NCT06811324
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
Studying: Semaglutide Injectable Product · NCT06706284
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Studying: Tirzepatide · NCT06751589
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Studying: SGLT2 inhibitor, GLP-1 receptor agonist · NCT05390892
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
Studying: Tirzepatide · NCT06774079
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Studying: Intervention 2: Semaglutide · NCT07361874
Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
Studying: Bimagrumab, Tirzepatide · NCT05933499
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Studying: semaglutide · NCT07040592
Tirzepatide to Slow Biological Aging
Studying: Zepbound · NCT07220473
Preoperative Weight Loss for Open Abdominal Wall Reconstruction
Abdominal Wall Hernia · NCT05925959
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
Studying: Semaglutide, Placebo · NCT07227948
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
Studying: Semaglutide · NCT05119179
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Studying: GLP-1, Ocrelizumab (US) · NCT07207148
Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
Studying: Radiotracer Injection, Contrast Media, Magnetic Resonance, Glucagon · NCT06252493
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Studying: Semaglutide Nasal Spray, Placebo, Semaglutide Injection · NCT07465965
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Studying: semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination) · NCT07213466
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Studying: NNC0519-0130, Placebo, Semaglutide · NCT06717698
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
Studying: Tirzepatide, Pioglitazone, Sitagliptin · NCT06246799
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Studying: Semaglutide Pen Injector, Placebo · NCT05819138
Effects of GH and Lirglutide on AgRP
Studying: growth hormone and lirglutide, growth hormone, liraglutide · NCT05681299
Transformative Research in Diabetic Nephropathy 2.0
Studying: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · NCT07444203
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
Studying: Tirzepatide · NCT06759701
A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs
Nutrition Intake, Nutrition Status, Gastrointestinal Microbiome · NCT07437911
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
Studying: Tirzepatide · NCT07095517
GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound
Gastric Retention · NCT07251803
Food and Fitness With Medicine (FFWM)
Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes · NCT07027995
Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy
Dietary Change, Obesity & Overweight, Food Acceptance · NCT07244445
Restoring Facial Volume After GLP-1 Weight Loss With Radiesse
Volume Loss (Soft Tissue Ptosis or Atrophy ) · NCT07419854
Incretin Microdosing for Cardiometabolic Health in People With HIV
Studying: Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly, Dose escalation to 2 mg semaglutide weekly then no semaglutide · NCT07325500
Effect of C-peptide on Hypoglycemic Counterregulation
Studying: C-peptide · NCT06470295
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Studying: Tirzepatide · NCT06517212
Semaglutide for Post-Smoking Cessation Weight Management
Studying: semaglutide 2.4mg, Placebo, Nicotine Replacement Therapy (NRT, nicotine patch) · NCT06173778
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.
Studying: Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone · NCT07224334
Impact GLP-1 Agonists Following Bariatric
Studying: GLP-1 receptor agonist · NCT06132477
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Studying: Tirzepatide · NCT06518837
Strength Training Response of Muscle in GLP-1 Users
Muscle Mass · NCT07104539
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
Studying: GLP-1, GIP · NCT01851694
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Studying: Tirzepatide, Placebo · NCT06802081
Stanford Pediatric Healthy Weight Index
Obesity & Overweight · NCT07316816
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
glp1 Agonist, Gene Expression, Skin Laxity · NCT07224880
Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
Obesity, Body Composition · NCT07226947
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Studying: Anti-Obesity Pharmacotherapy (Class Effect) · NCT07058155
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
Studying: Semaglutide (Rybelsus®), Placebo · NCT06338553
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Studying: Liraglutide · NCT07029009
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
Studying: Exendin 9-39, Saline · NCT06967558
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
Overweight and Obesity · NCT06069622
Splanchnic Venous Capacitance in Postural Tachycardia Syndrome
Studying: Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2, Compare change is SVC and SMA flow due to saline · NCT05375968
The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
Studying: Continue GLP/GIP · NCT07127354
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Studying: Semaglutide, Placebo · NCT06499857
Prevention of Progression of Prediabetes, Obesity and CV Risk
Studying: Placebo, Rybelsus Tablet, Jardiance 25Mg Tablet · NCT06446531
Tailored Exercise Training Study Among Adults With HFpEF
Studying: Weight loss · NCT07223242
Tirzepatide for Alcohol Use Disorder
Studying: Tirzepatide, Placebo injections · NCT06994338
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
Studying: Liraglutide Pen Injector · NCT06976619
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Studying: CagriSema (Cagrilintide B + semaglutide I) · NCT07184086
Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes
Prediabetes · NCT07210684
Insulin and Insulin Pulses During Fasting
PreDiabetes · NCT06424015
Semaglutide for Helping Opioid Recovery
Studying: Semaglutide · NCT06639464
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Studying: Tirzepatide, Lisdexamfetamine Dimesylate, Placebo (oral) · NCT06847399
Residual Gastric Content and GLP-1
Pre-op Gastric Emptying · NCT06814080
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
Studying: GLP-1 Receptor Agonists · NCT07169136
Tirzepatide in PWS, HO and GNSO
Studying: Tirzepatide · NCT06901245
Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication
Weight Loss, Food Selection · NCT06843512
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
Studying: Tirzepatide, Usual care medications · NCT07091734
The Effects of Bariatric Surgeries on Glucose Metabolism
Studying: Exendin-(9-39), Atropine · NCT02823665
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
Studying: exendin-(9-39), exendin -(9-39) · NCT01803451
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
Studying: Exendin-(9-39), Atropine, GLP-1 and GIP · NCT00992901
Impact of Semaglutide on Tobacco Use and Related Health Behaviors
Studying: Semaglutide, Placebo · NCT06986993
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
Studying: Semaglutide, Placebo · NCT06691243
Healthy Living BEYOND Weight Study
Overweight or Obesity · NCT07075341
Postprandial Response to Fruit Juice
Blood Glucose, Blood Insulin · NCT07103083
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
Studying: Metformin, Rapamycin, Naltrexone · NCT07092618
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
Studying: GLP-1 Receptor Agonists · NCT07012642
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Studying: Semaglutide Injectable Product (not provided by the study) · NCT05419726
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Studying: Tirzepatide · NCT06582875
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention · NCT06734312
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
Studying: Semaglutide Pen Injector [Ozempic], Placebo semaglutide pen injector · NCT04873050
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
Diabetes Mellitus · NCT06668935
Very Low Carbohydrate Diets and Glucagon Response in T1DM
Type1diabetes · NCT04200391
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Studying: Tirzepatide · NCT05912621
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Studying: Tirzepatide, Placebo · NCT05708859
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
Studying: Semaglutide Auto-Injector · NCT05780905
The T1D Exchange Registry
Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes · NCT04629586
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
Studying: Ribupatide · NCT07793929
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes
Studying: Semaglutide (Wegovy) weekly injection · NCT07797036
Ability of Almonds to Improve Nutrition During GLP-1 Treatment
Obesity, Type 2 Diabetes · NCT07796204
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Studying: Orforglipron, Placebo · NCT07794579
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity · NCT07760948
Digital Resistance Training for Midlife Women Using GLP-1
Women's Health, Obesity & Overweight, Perimenopausal Women · NCT07787533
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
Studying: Tirzepatide · NCT07349641
Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation
Diabetes · NCT07784127
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Studying: Zenagamtide, Semaglutide, Placebo (matched to semaglutide) · NCT07668414
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
Studying: Tirzepatide · NCT07782359
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Studying: Orforglipron, Dulaglutide · NCT07668336
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Studying: Semaglutide 1.0 mg, Semaglutide 2.0 mg · NCT07772960
Semaglutide in Youth With Autism Spectrum Disorder
Studying: Glucagon-like peptide-1 receptor agonist：Semaglutide · NCT07770152
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
Studying: Semaglutide · NCT07769047
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
Studying: NNC0721-8060, Semaglutide, Placebo · NCT07767175
Tirzepatide for Treatment of CCCA
Studying: Tirzepatide · NCT07734870
Comparing Facial Aging Between Identical Twins With 3D Imaging
Studying: GLP-1 Receptor Agonists · NCT07760532
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
Studying: Acute Ethanol Dose · NCT07758231
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
Studying: Tirzepatide, Loperamide, Diphenoxylate/Atropine · NCT07756359
Studies of Insulin and Glucagon Action in the Liver
Studying: Glucagon, Saline (placebo) · NCT07300982
GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD
Studying: Tirzepatide · NCT07747805
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Studying: Cagrilintide, Placebo cagrilintide, Placebo semaglutide · NCT07745504
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Obesity, Dental Care for Children · NCT07478653
Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)
Obesity · NCT07736729
Semaglutide for Low Back Pain
Studying: Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector) · NCT07731256
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
Studying: Phentermine Pill, Orforglipron · NCT07729332
Preoperative Semaglutide Prior to Radical Prostatectomy
Studying: Semaglutide 2.4 mg · NCT07727473
RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
Chronic Kidney Disease, Type 2 Diabetes · NCT07605390
Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
Weight Maintenance · NCT07701460
High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)
Weight Loss · NCT07700030
Combination Therapy for Alcohol Use Disorder
Studying: Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets) · NCT07249554
Imaging in Semaglutide Study
Type 2 Diabetes, BMI Greater Than 30 · NCT07695454
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
Studying: GLP1-RA (semaglutide) · NCT07627191
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Studying: Semaglutide 1.7mg subcutaneous, Placebo · NCT07021937
Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation
Weight Loss, GLP - 1, Weight Loss Maintenance · NCT07535892
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
Studying: Semaglutide · NCT06977438
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Studying: Semaglutide (Rybelsus®) · NCT07642635
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
Studying: Tirzepatide · NCT07078838
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Studying: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) · NCT07282613
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
Studying: Semaglutide, Tirzepatide, Microdose semaglutide · NCT07588984
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
Studying: Finerenone, Semaglutide, Lotensin · NCT07547878
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
Studying: Tirzepatide · NCT07298915
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
Studying: On GLP1 plus HRT, On GLP1 Only · NCT07558603
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
Studying: Semaglutide · NCT07554417
AIManage Using an AI-driven CDS and Chatbot
Diabetes, Obesity, Medication Side Effects · NCT07546357
Metabolic Surgery for Atrial Fibrillation Elimination
Studying: Anti-Obesity Medication (AOM) treatment · NCT07027969
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Studying: NA-931, Tirzepatide, Tirzepatide · NCT06732245
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Studying: NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111) · NCT07400107
GLP-1 RA for Stage 1 Type 1 Diabetes
Studying: Semaglutide, Placebo · NCT07430332
Human Models of Selective Insulin Resistance: Pancreatic Clamp
Studying: Insulin human, Octreotide Acetate, Glucagon · NCT06558422
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
Studying: Exendin 9-39 · NCT06972407
Evaluation of Sex Differences in Glucose Metabolism in Response to Sleep Curtailment
Sleep Deprivation, Sex Differences, Glucose Tolerance · NCT06809023
Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging
Laxity; Skin · NCT07216352
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists
Wrinkle · NCT07221461
Assess Impact of Poly-L-lactic Acid on GLP1 Subjects
Laxity; Skin · NCT07217743
Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy
Studying: GLP1 receptor agonist · NCT07175805
Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk
Type 2 Diabetes, Prediabetes, Liver Disease · NCT07032311
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
Studying: Metformin, GLP-1A · NCT06682351
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Studying: Semaglutide, Tirzepatide · NCT06803888
Semaglutide Therapy for Alcohol Reduction (STAR)
Studying: Semaglutide · NCT06015893
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Studying: Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab · NCT06299098
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Studying: Cagrilintide, Semaglutide, Placebo cagrilintide · NCT05567796
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Studying: Cagrilintide, Semaglutide, Placebo · NCT05669755
Avexitide for Treatment of Post-Bariatric Hypoglycemia
Studying: Avexitide · NCT06747468
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Studying: Retatrutide, Placebo · NCT06383390
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder
Studying: Tirzepatide · NCT07693608
Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy
Obesity Type 2 Diabetes Mellitus, Obesity · NCT07518407
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
Studying: Cagrilintide B, Cagrilintide D · NCT07605052
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Studying: Orforglipron, Placebo · NCT05869903
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Studying: SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA · NCT05220917
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
Type 2 Diabetes · NCT05040087
Weight Loss Management in Endometrial Cancer Survivors
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer · NCT06877572
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Studying: RO7204239, RO7204239 Matching Placebo, Tirzepatide · NCT06965413
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Studying: Semaglutide, Placebo · NCT05726227
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Studying: Cagrilintide, Placebo · NCT07220642
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Studying: Semaglutide, Placebo (semaglutide) · NCT03811561
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial
Studying: Tirzepatide · NCT06162715
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
Medullary Thyroid Carcinoma · NCT07713901
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Studying: Semaglutide, Placebo · NCT04822181
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Studying: VRB-101, Placebo · NCT07553299
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Studying: Cagrilintide, Placebo (matched to Cagrilintide) · NCT07220759
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Studying: Orforglipron, Placebo · NCT06993792
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Studying: Orforglipron, Placebo · NCT06972459
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
Studying: 4P004, Placebo (NaCl 0.9%) · NCT07225829
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Studying: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) · NCT07011667
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Studying: Retatrutide, Placebo · NCT07035093
Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
Studying: GLP-1 Therapy · NCT07313384
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
Pregnancy, Obesity, Overweight · NCT05503927
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Studying: semaglutide or tirzepatide · NCT07057310
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Studying: Retatrutide, Placebo · NCT06297603
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Studying: Retatrutide, Tirzepatide · NCT06662383
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Studying: LY3841136, Tirzepatide, Placebo · NCT06603571
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Studying: Semaglutide, Placebo · NCT06005012
A Study of a Novel Precision Medicine Approach For Obesity
Studying: Semaglutide, Placebo · NCT06814938
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying
Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting · NCT07140289
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Studying: Ribupatide, Placebo · NCT07458269
Comparison of Body Composition Changes With Weight Loss Interventions
Studying: GLP-1 receptor agonist · NCT07115069
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Studying: Liraglutide, Placebo · NCT04775082
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Studying: RO7795081, Semaglutide, Placebo · NCT07112872
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
Studying: Oral semaglutide, Sitagliptin · NCT07390110
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Studying: Tirzepatide, Placebo · NCT06075667
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
Studying: ECC4703, Placebo, Semaglutide · NCT07505303
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Studying: Semaglutide Pen Injector 2.4mg weekly · NCT05254314
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
Studying: Olatorepatide, Placebo · NCT07431086
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
Studying: Sotagliflozin, Volagidemab · NCT05696366
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Studying: Incretin-based therapies (GLP-1 and GLP-1/GIP) · NCT07640139
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Studying: Retatrutide · NCT07357415
Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)
Obesity, Body Weight Changes · NCT05622045
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
Studying: Semaglutide · NCT06571383
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
Studying: MET097, Placebo · NCT06973720
Triple Therapy in T1DM
Studying: Insulin, Semaglutide, Dapagliflozin · NCT03899402
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Studying: Orforglipron, Placebo · NCT06948422
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Studying: Orforglipron, Placebo · NCT06948435
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Studying: Orforglipron, Placebo · NCT06952530
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Studying: Bimagrumab, Tirzepatide, Bimagrumab Placebo · NCT06643728
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Studying: Tirzepatide, Semaglutide · NCT06980623
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Studying: Survodutide, Semaglutide · NCT06745284
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Studying: Tirzepatide, Placebo · NCT06914895
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Studying: Tirzepatide, Placebo · NCT05536804
Effects of Semaglutide in HIV-Associated Lipohypertrophy
Studying: Semaglutide Injectable Product, Placebo · NCT04019197
Liraglutide Effect in Atrial Fibrillation
Studying: Liraglutide, Anti Arrhythmics · NCT03856632
Saxenda: Underlying Mechanisms and Clinical Outcomes
Studying: liraglutide · NCT02944500
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Studying: Orforglipron, Placebo · NCT06972472
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Studying: Retatrutide, Placebo · NCT07232719
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Studying: Semaglutide Pen Injector, Placebo · NCT05067621
CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users
Obesity · NCT06467604
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Studying: Retatrutide, Semaglutide · NCT06260722
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
Studying: BMF-650 · NCT07223216
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
Studying: NT-0796, Placebo · NCT07220629
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Studying: VK2735 · NCT07104383
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
Studying: Islets of Langerhans transplantation · NCT00679042
To Determine Tolerability to Glucagon Infusion in Obese Subjects
Studying: Glucagon · NCT02817659
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
Studying: Glucagon, Glucagon, Placebo · NCT03139305
Surgical or Medical Treatment
Studying: Advanced Medical Therapy · NCT04128995
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Studying: Tirzepatide, Placebo · NCT06037252
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Studying: Retatrutide, Placebo · NCT06859268
Aleniglipron Phase 2 Body Composition Study
Studying: aleniglipron or placebo · NCT07169942
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Studying: AZD6234, Placebo to match · NCT06851858
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Obesity, Weight Change Trajectory, Weight Change, Body · NCT06484114
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
Studying: Tirzepatide, Placebo · NCT06962280
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
Studying: Dextrose, Clinisol 15% · NCT05264727
Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia
Studying: Glucagon for Injection (Fresenius Kabi USA) · NCT06986603
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Studying: glepaglutide · NCT03905707
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Studying: Cagrilintide, Semaglutide, Placebo cagrilintide · NCT06780449
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
Studying: Kidney-Protective Therapies Used in Routine Care · NCT07348718
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
Studying: Nimacimab injection, Nimacimab placebo injection, semaglutide injection · NCT06577090
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
Pregnancy, Obesity, Overweight · NCT05872022
DIALYSIS-TIR Study
Studying: Semaglutide, Placebo · NCT06042153
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Studying: Tirzepatide, Placebo · NCT05556512
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Studying: SGLT-2 inhibitor, GLP1-RA · NCT07325435
Brain Activation and Satiety in Children 2
Studying: Exenatide 2 mg [Bydureon], Placebo · NCT04520490
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
Studying: Semaglutide, Tirzepatide, Placebo · NCT06801015
The Long COVID Treatment Trial
Studying: Tirzepatide, Placebo · NCT07128082
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Studying: Tirzepatide, Antihyperglycemic medication · NCT05433584
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Studying: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) · NCT06797869
VK2735 for Weight Management Phase 3
Studying: VK2735 · NCT07104500
GLP-1s to Enhance Lasting Optimal Weight
Studying: Tirzepatide · NCT06861439
GLP-1 and Hypoglycemia
Studying: Glucagon-Like Peptide- 1 (GLP-1) infusion · NCT01858896
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Studying: Orforglipron, Placebo · NCT06649045
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Studying: Intervention, Active Comparator · NCT07188545
Anti-obesity Pharmacotherapy and Inflammation
Studying: Semaglutide, Phentermine-Topiramate combination, Phentermine · NCT05756764
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
Studying: GLP-1, Placebo · NCT07092605
Liver Glycogen and Hypoglycemia in Humans
Studying: Low Fructose, Saline, Somatostatin · NCT03241706
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
Studying: Apraglutide · NCT05018286
Tirzepatide for Obesity and Meth Use Disorder
Studying: Tirzepatide · NCT06745128
Effects of GRA in Patients With Type 1
Studying: REMD-477, Placebo · NCT04779645
Acupressure Wristbands for GLP-1RA Related Nausea
Nausea · NCT06939517
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Studying: bremelanotide, tirzepatide · NCT06565611
The Medically Reproducing Bariatric Surgery (MRB) II Study
Type 2 Diabetes, Obesity · NCT06363747
GLP_1 RA Ultrasound Study
Studying: Glucagon-Like Peptide-1 receptor agonists · NCT06581120
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma · NCT01511393